{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Progression of Disease"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Very Good Partial Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"The efficacy (as assessed by clinical response) of the combination of pomalidomide (CC-4047®) and romidepsin as therapy for patients with relapsed or refractory multiple myeloma (MM) (phase II portion) was evaluated using the IMWG Response Criteria for disease assessment. The best response was reported. (Criteria can be found at the following link, due to length and complexity of the response criteria: http://imwg.myeloma.org/international-myeloma-working-group-imwg-uniform-response-criteria-for-multiple-myeloma/)","groups":[{"description":"Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined","id":"OG000","title":"ALL Patients"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From baseline to cycle of maximum response, which occurred on average after 2 cycles; 1 cycle = 28 days","title":"Efficacy of Study Regimen Combination","type":"PRIMARY","unitOfMeasure":"Participants"}